# K042829: DBX Strip

- Pathway: 510(k) (Traditional)
- Applicant: Musculoskeletal Transplant Foundation
- Decided: Jan 13, 2006 after 458 days
- Product code: MBP (Filler, Bone Void, Osteoinduction (W/O Human Growth Factor))
- Device class: 2
- Regulation: 21 CFR 888.3045
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
No predicates in its family tree.
7 later devices descend from it; 4 cite it directly.
0 of 8 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- None. The FDA summary names no predicate by number.

## Most influential descendants
- K062205: DBX Strip (2007), 6 descendants of its own
- K113167: MTF New Bone Voild Filler (2012), 3 descendants of its own
- K110003: MTF New Bone Void Filler (2011), 3 descendants of its own
- K121989: Optecure Bone Void Filler (0.5 CC, 1CC, 2CC, 5CC, 10CC, and 20CC), Optecure + CCC Bone Void Filler (1CC, 2CC, 5CC, 10CC, (2012), 1 descendant of its own
- K241555: Moldable Bone Void Filler and Moldable Bone Void Filler + CCC (2025), 0 descendants of its own

## Indications for use
DBX® Strip is indicated as a bone void filler in the spine for the treatment of surgically created osseous voids or gaps that are not intrinsic to the stability of the bony structure. DBX Strip is indicated for use in the posterior elements of the spine for posterolateral fusion only. DBX Strip is for singzle patient use only.

Source page: https://510kreport.com/device/K042829
Methodology: https://510kreport.com/methodology